Your AI-Trained Oncology Knowledge Connection!
A panel discussion on changing treatment landscape of diffuse large B-cell lymphoma (DLBCL) and how new data from ASH 2021 on CAR-T therapies and antibody-drug conjugate are likely to change frontline treatment and sequencing of therapies in relapsed and refractory DLBCL going forward.
First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer
Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer
Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval
PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer
2 Commerce Drive
Cranbury, NJ 08512